To view this video, please enable marketing cookies from Cookie Preferences in the footer.
SGLT2 inhibitors (bexagliflozin,canagliflozin,dapagliflozin,empagliflozin,ertugliflozin) don’t just lower glucose and A1C, but these meds have become relevant in cardiovascular disease and chronic kidney disease in the right patients also with type 2 diabetes (T2DM). In this lecture from This is Why, Dr. Busti will make the SGLT2 inhibitors make sense as they provide cardiorenal protection above their improvements in A1C.
You’ll learn how to:
- Mechanism of action (MOA): how SGLT2 blockade drives glucosuria, modest A1c reduction, weight loss, and BP lowering
- Clinical use: where SGLT2 inhibitors fit for type 2 diabetes, plus major outcomes in heart failure and chronic kidney disease (CKD) (cardiorenal protection is a key reason they’re prioritized in modern guidelines)
- Key drugs (for exams + real-world practice): Empagliflozin (Jardiance), Dapagliflozin (Farxiga), Canagliflozin (Invokana), Ertugliflozin (Steglatro), and Bexagliflozin (Brenzavvy)
- Adverse effects & safety pearls: genital mycotic infections, volume depletion/hypotension, AKI considerations, and the “don’t-miss” rare events like euglycemic DKA (plus how to recognize it)
The goal = make medical education easy and clinically relevant.
Chapter Table of Contents
00:00 SGLT2 Inhibitors Overview & Clinical Importance
02:18 SGLT2 Drug Names (-gliflozin) & Sotagliflozin Exception
02:56 Indications & Evolving Uses: T2DM, HF, CKD, CV Risk
05:41 Net Clinical Benefits vs Other Diabetes Drug Classes
07:02 Core Mechanism: Renal Glucose Reabsorption Inhibition
12:36 Mechanism-Driven Side Effects: Diuresis & Infections
13:54 SGLT2s in Type 2 Diabetes Treatment Algorithms
18:02 When to Use vs Avoid SGLT2 Inhibitors (Comorbidities)
22:27 Dosing, Perioperative Holds & Euglycemic DKA Risk
25:03 Serious Adverse Effects: Fournier Gangrene & Hypotension
28:06 Fractures, Amputation Risk & Drug Interactions
30:36 Monitoring, Special Populations & Final Clinical Pearls
If this helped you, please like, subscribe to our YouTube Channel, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.
Don’t forget to turn on notifications on YouTube so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!
#sglt2inhibitors #empagliflozin #type2diabetes #diabetespharmacology #busti
Disclaimer:
This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.
More than just access—it’s where understanding deepens.
Create a free account or log in to gain access to this content!
Related Topics
